Karachi: The Searle Company Limited has reported a significant turnaround in its financial performance for the fiscal year 2026, with a notable increase in earnings per share (EPS) and a reduction in finance costs. The pharmaceutical company also outlined its growth strategy for the coming years, focusing on core pharmaceutical products and expanding its international market presence.
According to JS Global, Searle's consolidated net sales increased by 29% year-over-year to Rs36.8 billion in FY26, with gross margins expanding by 278 basis points to 52%. This improvement was achieved despite challenges such as inventory adjustments and seasonal effects in the fourth quarter. The company's finance costs fell by 48% to Rs1.09 billion, contributing to an EPS of Rs0.75, as opposed to a loss per share of Rs2.38 in the same period last year.
In the first quarter of FY27, Searle continued its positive momentum, with consolidated sales growing by 15% year-over-year to Rs11.2 billion, and EPS rising by 27% to Rs1.95. The company reported a gross margin expansion of 315 basis points to 57%. Management has set a target for annual revenue growth of 20-25% from FY27 to FY31, with the current revenue run rate and gross margin deemed sustainable barring significant external shocks.
Searle's portfolio is primarily focused on deregulated non-essential pharmaceuticals, with only 20% comprising essential drugs. The company has accelerated the launch of new products, including an iron supplement and various biosimilars. Despite rising costs for some active pharmaceutical ingredients, Searle has maintained healthy margins and strategically limited low-margin institutional sales.
The company is also investing in its biologics segment, which is growing at a rapid pace. Notable products include GLP-1 drugs, biosimilars for osteoporosis and bone cancer, and a long-term pipeline drug. Searle aims to achieve Rs1 billion in GLP-1 revenue in FY27 and capture a 20-25% market share within a year.
In addition to domestic growth, Searle is expanding its international footprint by entering new markets in Africa, Central Asia, and the Middle East, while prioritizing European markets over a US FDA application. The company is also upgrading its biological manufacturing facilities to support this expansion and reduce reliance on imported products.